Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

be used for patients with severe hepatic impairment. Patients with moderate renal impairment (CrCL = 20-39 mL/min) should receive a 50% decrease in the recommended starting dose and increased as tolerated. Doses greater than 600 mg are not recommended in patients with mild renal impairment (CrCL = 40-59 mL/min). For patients with moderate renal impairment doses greater than 400 mg are not recommended. Gleevec should be used with caution in patients with severe renal impairment.

Patients should be weighed and monitored regularly for signs and symptoms of edema, which can be serious or life-threatening. There have also been reports, including fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure and GI perforation.

Bullous dermatologic reactions (e.g., erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon re-challenge. Several post-marketing reports describe patients able to tolerate the reintroduction of Gleevec at a lower dose with or without concomitant corticosteroids or antihistamines following resolution or improvement of the bullous reaction.

Consider potential toxicities--specifically liver, kidney and cardiac toxicity, and immunosuppression from long-term use.

Gleevec is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6 and CYP2C9. Dosage of Gleevec should increase by at least 50%, and clinical response should be carefully monitored in patients receiving Gleevec with a potent CYP3A4 inducer such as rifampin or phenytoin. Examples of commonly used drugs that may significantly interact with Gleevec include ketoconazole, acetaminophen, warfarin, erythromycin and phenytoin. (Please see full Prescribing Information for other potential drug interactions.)

For daily dosing of 800 mg and above, dosing should be accomplished using the 400 mg tablet to reduc
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) ... secured $1 million in 12% per annum short term ... is an initial drawdown of $500,000, with accrued interest ... of $500,000 with accrued interest and principal repayable in ... Company becoming cashflow positive for any calendar month prior ...
(Date:12/16/2009)... December 16 Scientists at,deCODE genetics, Inc. ... the,discovery of a version of a common single-letter ... with a major impact on susceptibility to type ... is not only large, but unusual:,if an individual ... risk of,T2D by more than 30% compared to ...
(Date:12/16/2009)... Wis., Dec. 16 EuroPharma, Inc. ... for the use of super absorbency BCM-95® ... EuroPharma formulations. The exclusive distribution territory ... health food store channel and professional channel, ... and clinics. BCM-95® is a highly ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 1Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 2Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 3Award recognizes 30 years of anti smoking work 59213 1Award recognizes 30 years of anti smoking work 59213 2Developing enzymes to clean up pollution by explosives 10312 1
... Results presented at the Movement Disorder Society's 11th,International ... 08, 2007 /PRNewswire-FirstCall/ -- New,information on the use ... disease (PD) was reported this week at The,Movement ... approved by the FDA May 17, 2006, for ...
... 8, 2007 - AVANIR,Pharmaceuticals (NASDAQ:AVNR) today ... including efficacy, safety and improvements in,patient-centered ... (DPN) pain treated with the investigational ... and sigma-1 agonist. The data were ...
Other Medicine Technology:International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 2International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 3International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 4International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 5International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 4AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 5AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 7
(Date:12/16/2009)... 16 New Enterprise Associates, Inc. (NEA), ... that one of its portfolio companies, Acclarent, Inc., ... acquired by Ethicon, Inc., a Johnson & Johnson ... million (net of estimated cash on hand at ... to designing, developing and commercializing devices that address ...
(Date:12/16/2009)... Immucor, Inc. (Nasdaq: BLUD ), a ... blood transfusion industry, today announced that Paul D. Mintz, ... new independent director, effective January 1, 2010. ,, ... transfusion medicine for more than 30 years. He is ... University of Virginia School of Medicine. He also serves ...
(Date:12/16/2009)... For wounded U.S. servicemen and women recovering at Walter ... can be a particularly difficult time. Wounded soldiers ... ever on the healing power of connecting with family ... easier for Walter Reed patients as Verizon Wireless donated ... of minutes of holiday talk time for 2,500 recovering ...
(Date:12/16/2009)... 16 HealthSciences Institute will sponsor ... professionals, teams and organizations who serve individuals ... diseases in employer, health plan, medical home ... will offer free, noncommercial webinars on topics, ... prevention, management and care improvement. Each webinar ...
(Date:12/16/2009)... suggests it plays a role in reducing inflammation in ... A gene variant that plays a role in inflammation ... as well as adults who smoke. , Researchers also ... MMP12 gene had a lower risk of developing chronic ... on by smoking. , "The gene seems to be ...
Breaking Medicine News(10 mins):Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Immucor Appoints New Board Director 2Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3
... of Texas, 181,legislators are being honored with the ... accomplishments on behalf of health care,during the 80th ... created the award in 1997 to honor state ... on issues important,to hospitals and health systems. ...
... WASHINGTON, Oct. 15 Arthur H. Rubenstein,MBBCh, executive vice ... medicine, and Robert G. Dunlop professor of medicine at ... board of directors of the,Association of Academic Health Centers., ... School of Medicine in New,York before assuming his current ...
... pose big stomach risks, study notes , , MONDAY, ... don,t tell their doctors that they take common over-the-counter ... omission, a new study has found. , "With nearly ... it is no wonder that adverse events are increasing ...
... PA and VANCOUVER, BC, Oct. 15 /PRNewswire/ - ... pain drugs, announced today it has successfully reached ... (FDA) under the,Special Protocol Assessment (SPA) process for ... (OROS(R) Hydromorphone) for the treatment of,chronic pain. A ...
... Calif., Oct. 15 Edwards Lifesciences,Corporation (NYSE: EW ... advanced cardiovascular disease, plans to announce its operating,results for ... closes on,Monday, October 22, 2007 and will host a ... its results. To participate in the conference call, ...
... by gift from P&G, PHILADELPHIA, Oct. 15 ... for Clinical Research & Education,today announced a commitment ... gift to the ACG Institute,s Capital Campaign boosts ... in more than $16 million to,support clinical research, ...
Other Medicine News:Health News:THA Honors Nine Legislators for Contributions to Health Care 2Health News:Association of Academic Health Centers Names University of Pennsylvania's Dr. Arthur H. Rubenstein Chairman of the Board of Directors 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 3Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 2Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 3Health News:Edwards Lifesciences to Host Earnings Conference Call on October 22, 2007 2Health News:ACG Announces Generous Gift by Procter & Gamble 2
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Available in 5, 8 and 12 mm bite, with and without teeth....
...
...
Medicine Products: